🔎 Trials Near Me

Home › Mild Cognitive Impairment › NCT05151562

Music Therapy for Patients With Alzheimer's Disease

Recruiting

Music Therapy for Autobiographical Memory and Neuropsychiatric Symptoms in Alzheimer Disease

Who can join

Ages 18 to 89 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Age 18-89
* Mild Cognitive Impairment (MoCA score: 18-25) or Early AD (MoCA score: 17-24)

Exclusion Criteria:

* Head trauma, traumatic brain injury, or concussion with loss of consciousness for \>2 minutes
* Claustrophobia incompatible with MRI scanning
* Medical device incompatible with MRI scanning (e.g. cardiac pacemaker, implanted cardiac defibrillator, aneurysm brain clip, inner ear implant)
* Prior history as a metal worker and/or certain metallic objects in the body
* Exclusion Criteria will be carefully determined by the MRI screening form.

About the study

This study is designed to assess the feasibility that individualized reminiscence-based virtual music therapy sessions can enhance autobiographical memory, mood, and cognition in patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD).

60 patients with MCI or mild dementia due to AD will receive two 30 minutes reminiscence-targeted virtual music therapy interventions per week for 8 weeks (a total of 16 sessions).

Participants' (or supported by the study partner) self-reported and measurable outcomes including cognitive, anxiety, quality of life, and autobiographical memory will be assessed before and after the 8-week course of treatment. Blood-oxygenation level-dependent (BOLD) in functional magnetic resonance imaging (fMRI) will also be also measured before and after the 8-week course of treatment.

What is being tested

Sponsor: Johns Hopkins University · Participants: 60 · Started: Jul 18, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05151562

Locations in the U.S.

MarylandJohns Hopkins School of Medicine, Baltimore

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.